A systematic review, published in the European Journal of Ophthalmology, has reported a significant number of peer-reviewed studies on ophthalmic-focused COVID-19 articles. A study conducted… Read More »A systematic review has reported ophthalmology-focused publications and findings on COVID-19 pandemic.
A French surgical-robotics company in Montpellier, “AcuSurgical”, has announced a Series A funding of around €5.75 million for an advanced robotic microsurgical platform for the… Read More »“AcuSurgical”, a robotics company for retinal microsurgery based in Montpellier, France, has raised €5.75M funding.
Researchers at the Department of Ophthalmology, at the University of Milan, have published the largest molecular study of Italian patients with RP in the literature. … Read More »The largest molecular study of RP in Italy has reported 591 probands with family history and sporadic cases.
Dear EURETINA Members, A very warm welcome to the February 22nd, 2021 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are… Read More »February 22nd, 2021: “EURETINA-Brief”© Issue No. 230
A US biotechnology company, Advernum Biotechnologies Inc., (NASDAQ:ADVM), has announced the enrolment of a Phase 2 study for the treatment of diabetic macular edema (DME),… Read More »Advernum Biotechnologies Inc., (NASDAQ: ADVM) expects to enrol Phase 2 patients for a treatment for DME using the aflibercept gene.
Research on road driving testing with participants with ocular diseases, compared to aged-matched controls, has shown a significant time delay on a useful hazard perception… Read More »Research on hazard perception testing (HPT) among older drivers with eye disease can be improved with training.
A novel research report, published in Ophthalmology Science (Jan. 11th 2021) has identified a genetic association between the MMP9 gene (matrix metalloproteinase-9) and exudative AMD. … Read More »First confirmation of genetic association with MMP9 and exudative age-related macular degeneration (AMD).
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the February 2nd, 2021 edition of EURETINA’s web-based digital magazine,… Read More »February 2nd, 2021: “EURETINA-Brief”© Issue No. 229
A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the enrolment of a phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), expects to enrol 36 patients of LCA10 using a novel therapy for “Sepofarsen” (QR-110)
An estimate of 100,000 ophthalmic appointments have been cancelled by a single hospital (Moorfields, London, UK) over a 3-month duration due to the COVID-19 pandemic. … Read More »Stay-at-home visual evaluations provide an innovative tool for printable visual acuity (VA) charts